Atricure (ATRC) Receives a Buy from Stifel Nicolaus
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Atricure (ATRC) with a $50 price target. Piper Sandler's Matthew O'Brien also issued a Buy rating today, while Oppenheimer maintained a Hold rating on the stock.
In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Atricure, with a price target of $50.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Wise covers the Healthcare sector, focusing on stocks such as Solventum Corporation, Atricure, and Boston Scientific. According to TipRanks, Wise has an average return of -2.5% and a 45.20% success rate on recommended stocks.
In addition to Stifel Nicolaus, Atricure also received a Buy from Piper Sandler’s Matthew O’Brien in a report issued today. However, on the same day, Oppenheimer maintained a Hold rating on Atricure (NASDAQ: ATRC).